Innovative Findings from TScan Therapeutics at ACR Convergence
TScan Therapeutics Makes Waves at ACR Convergence 2025
WALTHAM, Mass. – TScan Therapeutics, Inc. (NASDAQ: TCRX), a cutting-edge biotechnology company dedicated to the development of T cell receptor-engineered T cell (TCR-T) therapies, is thrilled to announce their participation at the prestigious American College of Rheumatology (ACR) Convergence 2025. This event takes place from October 24th to 29th in Chicago, showcasing the latest innovations in rheumatology.
Presenting Innovative Research
During the conference, TScan will be presenting two pivotal abstracts focusing on their research related to T cell-driven autoimmune disorders. This marks a significant milestone as they extend their focus beyond oncology into autoimmunity through their proprietary TargetScan technology.
Innovative Oral Presentation
One of the highlights is the oral presentation titled "TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis". This session promises to illuminate the shared T-cell targets identified in Ankylosing Spondylitis (AS), a disease that has historically posed challenges in terms of understanding therapeutic targets.
Details of the Oral Presentation
Authors: Adam Weinheimer, Olivia Pryor, Catalina Burbano and others.
Abstract Number: 0888
Session Name: T Cell Biology & Targets in Autoimmune & Inflammatory Disease
Session Date/Time: Monday, October 27; 10:00 - 11:30 a.m. Central Time
Presentation Time: 10:45 - 11:00 a.m. Central Time
Location: Poster Hall
Poster Presentation Insights
TScan will also unveil a poster presentation titled "Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan". This work reinforces their commitment to leveraging technology to drive research in autoimmune disorders.
Details of the Poster Presentation
Authors: Olivia Pryor, Catalina Burbano, Nathaniel Bagge, Rutuja Kulkarni and others.
Abstract Number: 0997
Session Name: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
Session Date/Time: Monday, October 27; 10:30 a.m. - 12:30 p.m. Central Time
Location: Poster Hall
TScan's Commitment to Innovation
TScan aims to address the complexities of autoimmune diseases. The insights gained from these studies highlight their ongoing commitment to enhancing therapeutic strategies using their unique TargetScan approach. Gavin MacBeath, Ph.D., Chief Executive Officer, emphasizes the excitement surrounding the initial findings, particularly in locating significant T-cell targets in AS. The advancements in this research could shape the future of drug development in autoimmune conditions.
About TScan Therapeutics
Founded to innovate the realm of T cell therapies, TScan Therapeutics focuses on creating TCR-T therapies for patients suffering from cancer. With two essential programs currently active—ALLOHA™ for hematologic malignancies and PLEXI-T™, aimed at solid tumors—they are moving the field forward. Their ImmunoBank serves as a repository of therapeutic TCRs, which enables them to develop a variety of personalized treatment options.
Contact Information
For further information, reach out to:
Heather Savelle
VP, Investor Relations
TScan Therapeutics, Inc.
Phone: 857-399-9840
hsavelle@tscan.com
Frequently Asked Questions
What is TScan Therapeutics primarily focused on?
TScan Therapeutics focuses on developing T cell receptor-engineered T cell therapies for cancer and autoimmune disorders.
Where will TScan be presenting their findings?
The presentations will take place at the ACR Convergence 2025 in Chicago, scheduled for October.
What are the main topics of TScan's presentations?
TScan will discuss their findings related to Ankylosing Spondylitis and autoantigens in Scleroderma and Ulcerative Colitis.
What technology does TScan utilize for their research?
TScan utilizes their proprietary TargetScan technology to identify T-cell targets.
How can I learn more about TScan's progress?
Interested individuals may contact TScan’s investor relations or visit their official website for updates.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.